Renin–angiotensin system inhibitors positively impact on multiple aging regulatory pathways: Could they be used to protect against human aging? DOI Creative Commons
Elena M. V. de Cavanagh, Felipe Inserra, León Ferder

et al.

Physiological Reports, Journal Year: 2024, Volume and Issue: 12(12)

Published: June 1, 2024

The renin-angiotensin system (RAS)-a classical blood pressure regulator-largely contributes to healthy organ development and function. Besides, RAS activation promotes age-related changes age-associated diseases, which are attenuated/abolished by RAS-blockade in several mammalian species. RAS-blockers also increase rodent lifespan. In previous work, we discussed how downregulates mTOR growth hormone/IGF-1 signaling, stimulates AMPK activity (together with klotho, sirtuin, vitamin D-receptor upregulation), proposed that at least some of RAS-blockade's aging benefits mediated through regulation these intermediaries their signaling mitochondria. Here, included impact on other regulatory pathways, is, TGF-ß, NF-kB, PI3K, MAPK, PKC, Notch, Wnt, all affect No direct evidence is available RAS/RAS-blockade-aging pathway-mitochondria interactions. However, existing results allow conjecture neutralize mitochondrial dysfunction acting the pathways. reviewed led us propose foundation laid for conducting clinical trials aimed testing whether angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)-even subclinical doses-offer possibility live longer better health. As ACEi ARB low cost well-tolerated anti-hypertension therapies use over 35 years, investigating administration attenuate/prevent effects seems simple implement.

Language: Английский

Modulation of M1 and M2 macrophage polarization by metformin: Implications for inflammatory diseases and malignant tumors DOI
Sara Jafarzadeh, Maryam Nemati, Raziyeh Zandvakili

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 151, P. 114345 - 114345

Published: March 1, 2025

Language: Английский

Citations

1
Microenvironment-based immunotherapy in oral cancer: a comprehensive review DOI

Hassan Mivehchi,

Aisan Eskandari-Yaghbastlo,

Masumeh Ghazanfarpour

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(5)

Published: March 28, 2025

Language: Английский

Citations

1
The role of neuroinflammation in the transition of acute to chronic pain and the opioid-induced hyperalgesia and tolerance DOI Creative Commons
Marco Echeverria-Villalobos, Vı́ctor Tortorici, Beatriz E. Brito

et al.

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: Dec. 15, 2023

Current evidence suggests that activation of glial and immune cells leads to increased production proinflammatory mediators, creating a neuroinflammatory state. Neuroinflammation has been proven be fundamental mechanism in the genesis acute pain its transition neuropathic chronic pain. A noxious event stimulates peripheral afferent nerve fibers may also activate pronociceptive receptors situated at dorsal root ganglion horn spinal cord, as well cells, setting off so-called sensitization spreading neuroinflammation brain. Once activated, microglia produce cytokines, chemokines, neuropeptides can increase sensitivity firing properties second-order neurons, upregulating signaling nociceptive information cerebral cortex. This process, known central sensitization, is crucial for chronification Immune-neuronal interactions are implicated lesser-known complex regulatory relationship between opioids. activated alter neuronal function, induce, maintain pathological pain, disrupt analgesic effects opioid drugs by contributing development tolerance dependence, even causing paradoxical hyperalgesia. Such alterations occur when environment impacted trauma, inflammation, immune-derived molecules, or opioids induce activation. Hence, understanding these intricate help managing efficacy beyond classical pharmacological approach.

Language: Английский

Citations

17
ECM-based Ca2+/l-arginine/NO periosteum nourishes bone defect microenvironment, directs macrophage polarity, and accelerates osteogenesis and angiogenesis DOI

Ho‐Pan Bei,

Xiongfa Ji, Tianpeng Xu

et al.

Composites Part B Engineering, Journal Year: 2024, Volume and Issue: 278, P. 111410 - 111410

Published: March 27, 2024

Language: Английский

Citations

7
Renin–angiotensin system inhibitors positively impact on multiple aging regulatory pathways: Could they be used to protect against human aging? DOI Creative Commons
Elena M. V. de Cavanagh, Felipe Inserra, León Ferder

et al.

Physiological Reports, Journal Year: 2024, Volume and Issue: 12(12)

Published: June 1, 2024

The renin-angiotensin system (RAS)-a classical blood pressure regulator-largely contributes to healthy organ development and function. Besides, RAS activation promotes age-related changes age-associated diseases, which are attenuated/abolished by RAS-blockade in several mammalian species. RAS-blockers also increase rodent lifespan. In previous work, we discussed how downregulates mTOR growth hormone/IGF-1 signaling, stimulates AMPK activity (together with klotho, sirtuin, vitamin D-receptor upregulation), proposed that at least some of RAS-blockade's aging benefits mediated through regulation these intermediaries their signaling mitochondria. Here, included impact on other regulatory pathways, is, TGF-ß, NF-kB, PI3K, MAPK, PKC, Notch, Wnt, all affect No direct evidence is available RAS/RAS-blockade-aging pathway-mitochondria interactions. However, existing results allow conjecture neutralize mitochondrial dysfunction acting the pathways. reviewed led us propose foundation laid for conducting clinical trials aimed testing whether angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)-even subclinical doses-offer possibility live longer better health. As ACEi ARB low cost well-tolerated anti-hypertension therapies use over 35 years, investigating administration attenuate/prevent effects seems simple implement.

Language: Английский

Citations

6